

A Comparison Between Effectiveness of Intravenous Magnesium Sulphate and Dexmedetomidine on Attenuation of Haemodynamic Stress Response to Laryngoscopy and Endotracheal Intubation: A Randomised Control Trail

ABSTRACT

Introduction: Hemodynamic stress responses to laryngoscopy and endotracheal intubation, can pose significant risks, especially in patients with cardiovascular comorbidities. This study aimed to compare the efficacy of magnesium sulphate and dexmedetomidine in attenuating these responses.

Methods: A randomized controlled trial was conducted on 80 patients (40 in each group), aged 18-60 years, undergoing elective surgeries under general anesthesia at Meenakshi Mission Hospital, Madurai. Patients were randomized into two groups: Group M received 30 mg/kg magnesium sulphate, and Group D received 0.75 mcg/kg dexmedetomidine. Hemodynamic parameters (heart rate, systolic, diastolic, and mean arterial pressure) were measured at baseline, after drug administration, and at 1, 3, and 5 minutes post-intubation. Data were analyzed using Student t-tests and chi-square tests, with $p < 0.05$ considered significant.

Results: Dexmedetomidine (Group D) showed significantly lower heart rate and systolic blood pressure at all post-intubation intervals compared to magnesium sulphate (Group M). Specifically, Group D demonstrated lower mean heart rates at 3 minutes post-drug (77.3 ± 15.8 vs 86.5 ± 13.0 ; $p=0.006$) and 5 minutes post-intubation (72.1 ± 9.8 vs 77.1 ± 11.5 ; $p=0.04$). Systolic blood pressure was also significantly lower in Group D at 1 minute post-intubation (123.7 ± 16.1 vs 136.9 ± 12.6 ; $p=0.001$). Complication rates were low in both groups, though hypotension occurred more frequently in Group D (10% vs 2.5%, $p=0.166$).

Conclusion: Dexmedetomidine was more effective than magnesium sulphate in attenuating the hemodynamic stress response to laryngoscopy and intubation, with a slightly higher incidence of hypotension. Both agents were generally safe and well-tolerated.

Keywords: Laryngoscopy, Endotracheal Intubation, Hemodynamics, Magnesium Sulfate, Dexmedetomidine

1. INTRODUCTION

Both laryngoscopy and endotracheal intubation are common airway management methods used in emergency medical care and surgery [1]. However, they are commonly linked to notable hemodynamic reactions that are characterized by sympathetic activation resulting in an elevation of blood pressure, heart rate, and plasma catecholamine levels. This condition, which is also known as the "pressor response," might put patients at serious risk, particularly those who have intracranial diseases, hypertension, or cardiovascular comorbidities [2,3]. Therefore, it is essential to attenuate this hemodynamic stress response to lower perioperative morbidity and death among patients undergoing laryngoscopy and endotracheal intubation.

The primary cause of the laryngoscopic stress reaction is the activation of mechanoreceptors in the larynx, epiglottis, and pharyngeal wall. These receptors then set off a series of autonomic reflexes through the sympathetic nervous system [4]. These reflexes cause an abruptly increase the catecholamine release, which raises heart rate and blood pressure resulting in myocardial ischemia, cerebrovascular accidents, or other harmful cardiovascular effects [5]. Thus, controlling this reaction has gained attention in contemporary anaesthesiology, and many pharmaceutical treatments have been investigated for their potential to reduce this pressor response [6].

Numerous medications, such as beta-blockers, calcium channel blockers, opioids, and local anaesthetics, have been studied for their potential to lessen this hemodynamic response; yet, the quest for the ideal treatment modality persists. Recent years have seen an increase in interest in two pharmacological drugs namely magnesium sulphate and dexmedetomidine, due to their potential to modify the cardiovascular response during laryngoscopy and intubation [7].

Magnesium sulfate is a divalent cation that has anti-nociceptive, vasodilatory, and anti-arrhythmic effects in addition to acting as a calcium channel blocker.

Magnesium sulfate reduces sympathetic outflow by blocking catecholamine release from peripheral nerve endings and the adrenal medulla. This may lessen the tachycardic and hypertensive response that occurs during airway manipulation.

Magnesium also functions as an N-methyl-D-aspartate (NMDA) receptor antagonist, which may be part of the reason for its ability to reduce nociception and improve perioperative analgesia. Magnesium sulfate has a broad pharmacological profile, which makes it a promising drug to reduce the hemodynamic stress response [8].

An alpha-2 adrenergic receptor agonist with a unique mode of action is dexmedetomidine. By lowering sympathetic tone and preventing the release of norepinephrine from pre- and post-synaptic alpha-2 receptors in the central nervous system, it causes drowsiness, analgesia, and anxiolysis. Apart from its central actions, dexmedetomidine also causes peripheral vasodilation, which helps lessen the pressure reaction to intubation and laryngoscopy [6]. The drug's benefits for anaesthesia include steady hemodynamics, a decreased need for anaesthetic, and a sedative profile without respiratory depression. As a result, dexmedetomidine has become more widely used in perioperative care, particularly for its ability to reduce

the hemodynamic reaction to airway instrumentation [9]. There is a paucity of research especially from India, that has compared the use of these drugs in attenuation of hemodynamic stress response to laryngoscopy and endotracheal intubation, Thus, we decided to take up this study.

Aim:

To evaluate the effectiveness and complications of magnesium sulphate and dexmedetomidine in attenuating hemodynamic stress response to laryngoscopy and intubation.

2. MATERIAL AND METHODS

2.1 Study design and setting:

We conducted a randomized control trial among patients aged 18 to 60 years, with inclusion criteria of i) Undergoing Elective Surgeries Under General Anaesthesia ii) Mallampati Class I and II iii) Belonging to ASA Grade I and II admitted in Meenakshi mission hospital and research centre, Madurai over a period of 2 years [August 2019 – October 2020]. We excluded the following patients: i) Had anticipated difficult airway ii) Laryngoscopy time exceeded 15 seconds iii) History of hiatus hernia or full stomach or GERD (gastroesophageal reflux disease) iv) Physically dependent on narcotics, drugs or alcohol abuse v) Pregnant women and vi) Patient on beta blockers

2.2 Sample size:

The sample size was calculated based on the previous study done by Krishna Chaithanya et al⁽¹⁰⁾ assuming power at 80% and confidence interval at 95% with Group 1 and 2 mean [SD] to be 80.5 (13.8) & 89.4 (13.5), using the formula:

$$n_1 = \frac{(\sigma_1^2 + \sigma_2^2 / K)(z_{1-\alpha/2} + z_{1-\beta})^2}{\Delta^2}$$
$$n_2 = \frac{(K * \sigma_1^2 + \sigma_2^2)(z_{1-\alpha/2} + z_{1-\beta})^2}{\Delta^2}$$

The final sample size was arrived at 40 in each group [80 in total]

Randomisation and Allocation concealment:

Patients who fulfilled the inclusion and exclusion criteria and were willing to participate in the study were allotted to either of the 2 groups based on computer-generated randomization. The random numbers were generated using the statistical software STATA version14 (Texas, USA) and allocated into:

Group M received Magnesium sulphate 30mg/kg diluted to 50 ml with normal saline

Group D received Dexmedetomidine 0.75mcg/kg diluted to 50 ml with normal saline

Allocation concealment was ensured using the SNOSE [Sequentially numbered opaque sealed envelopes]

2.3 Study procedure:

After obtaining institutional ethical committee approval (IEC), 80 patients belonging to ASA grade I and II aged between 18-60 years of either gender, who fulfilled the

inclusion and exclusion criteria posted for elective surgeries under general anaesthesia were assigned to the study. Demographic data were recorded. All patients were evaluated for anaesthesia fitness and surgical procedures on the day before surgery. A thorough history was obtained and a clinical examination was performed.

On the day of surgery, the patient was identified and all vital parameters, NPO status, consent for anaesthesia and consent for study were checked. The procedure was done under the guidance of a senior consultant anesthesiologist. The patient was shifted to operating room and intravenous (IV) access was secured, standard monitoring including ECG, NIBP, and pulse oximeter were connected and the baseline heart rate, systolic blood pressure, diastolic blood pressure and mean arterial pressure were noted. All patients received injection of glycopyrolate 0.2mg intravenously as premedication half an hour before induction. Patients were divided into two groups by computer-based randomisation. After completing either magnesium sulphate or dexmedetomidine infusion, before inducing the patient, heart rate, systolic blood pressure, diastolic blood pressure and mean arterial pressure were noted. The patient was pre-oxygenated for 3 minutes with 100% oxygen and induced with IV fentanyl 1.5mcg/kg, and IV propofol 1.5mg/kg. After checking for the ease of bag-mask ventilation, the patient was paralyzed with IV rocuronium 1mg/kg and bag-mask ventilation was done for 1 minute with 100% oxygen and patient's heart rate, systolic blood pressure, diastolic blood pressure and mean arterial pressure were noted.

After 1 minute of assisted mask ventilation, laryngoscopy and endotracheal intubation was done. The duration of laryngoscopy and intubation was limited to the minimum possible time and was less than 15 seconds for all patients. Proper placement of the endotracheal tube and ventilation was checked by auscultation of breath sounds and capnography. Then the patient was connected to a mechanical ventilator and ventilated using volume-controlled ventilation mode. Anaesthesia was maintained with O₂ and N₂O in the ratio of 50% each and isoflurane 1vol%. Hemodynamic parameters were measured before magnesium sulphate/dexmedetomidine infusion (baseline), 3 minutes after the study drug (before induction), 1 minute after induction, 1 minute, 3 minutes and 5 minutes after intubation. At the end of surgery, patients were reversed with neostigmine 0.05mcg/kg and glycopyrrolate 0.01mcg/kg.

The hemodynamic parameters monitored included: **i)** Heart rate **ii)** Systolic blood pressure **iii)** Diastolic blood pressure **iv)** Mean arterial pressure

These parameters were measured at the following intervals:

- i) baseline (before study drug),
- ii) 3 minutes after the study drug (before induction),
- iii) 1 minute after induction,
- iv) 1 minute after intubation,
- v) 3 minutes after intubation,
- vi) 5 minutes after intubation.

Complications like hypotension, bradycardia and desaturation were noted with the definition:

1. Hypotension – systolic blood pressure less than 30% of patient's baseline value or systolic blood pressure less than 90 mmHg whichever is lower.

2. Bradycardia - heart rate less than 20% of patient's baseline value or heart rate less than 50 beats per minute whichever is lower. If heart rate less than 50 beats per min, that was treated with injection atropine 0.6 mg
3. Desaturation - oxygen saturation less than 90%. And if the patient get desaturates, supplemented with 100% O₂ through face mask.

2.4 Statistical analysis:

All necessary information was collected and entered into a Microsoft Excel worksheet. Data analysis was done with the help of a computer using SPSS Statistics 26.0 software (SPSS Inc. Bangalore India). The chi-square test and Fisher's exact test were used to find out the association between the categorical variables. Independent's 'T-test was used to find the significance of the difference between groups. A 'p' value less than 0.05 was considered statistically significant. The performed the analysis based on per protocol analysis

2.5 Ethical clearance:

The patient and attendees were explained about the procedure and the expected complications. They were informed about the present study and their eligibility for participating in the study. Only patients who were willing to participate were included and informed consent was obtained. The study was approved by the Institutional Ethical Committee [NBE/CNC/CET/41159]

3. RESULTS

We finally recruited around 80 patients [40 in each group] who fulfilled the inclusion criteria [0% non-response rate]. The comparison of sociodemographic and baseline hemodynamic parameters across the study groups is explained in **Table 1**. The mean age in group M was 44.3 ± 8.6 years and in group D was 42.4 ± 11.0 years, and mean weight in group M was 59.0 ± 8.1 kg and in group D was 62.2 ± 9.1 kg. In group M 21 (52.5%) were male patients and 19 (47.5%) were female patients. In group D 25 (62.5%) were male patients and 15 (37.5%) were female patients. The percentage of patients belonging to ASA I and II in group M was 16 (40%) and 24 (60%) respectively. The percentage of patients belonging to ASA I and II in group D was 20 (50%) and 20 (50%) respectively. There was no statistically significant difference in the sociodemographic variables in the two groups ($p=0.05$) and they were comparable.

Table 1: Comparison of sociodemographic and baseline hemodynamic parameters across the study groups, N=80

Parameter	Group M	Group D	Students T test (t value)	p-value
	Mean \pm SD	Mean \pm SD		
Age (years)	44.3 ± 8.6	42.4 ± 11.0	-0.8837	0.38

Weight (kg)	59.0 ± 8.1	62.2 ± 9.1	1.7084	0.09
Baseline hemodynamic parameters				
HR (beats/min)	83.5 ± 13.4	88.8 ± 14.9	1.6707	0.09
SBP (mm of Hg)	138.7 ± 11.8	136.6 ± 12.9	-0.7680	0.44
DBP(mm of Hg)	82.2 ± 9.1	83.5 ± 9.0	0.6575	0.51
MAP(mm of Hg)	99.6 ± 8.4	99.2 ± 7.9	-0.2052	0.82
Parameter	N (%)	N (%)	Chi square ()	p-value
Gender				
Male	21 (52.5)	25 (62.5)	0.8184	0.36
Female	19 (47.5)	15 (37.5)		
ASA status				
I	16 (40.0)	20 (50.0)	0.8081	0.36
II	24 (60.0)	20 (50.0)		

Table 2: Comparison of hemodynamic parameters [Heart rate, systolic & diastolic blood pressure, and mean arterial pressure during the time intervals across the study groups, N=80

Parameter	Follow up time	Group M	Group D	Students T test (t value)	P-value
		Mean ± SD	Mean ± SD		
Heart Rate (beats per minute)	Base line	83.5 ± 13.4	88.8 ± 14.9	1.6707	.099 NS
	3 min after study drug	86.5 ± 13.0	77.3 ± 15.8	-2.8534	.006 Sig
	1 min after induction	79.4 ± 12.5	72.2 ± 11.7	-2.6690	.009 Sig
	1min after intubation	90.1 ± 11.7	78.4 ± 9.3	-4.9552	.001 Sig
	3 min after intubation	81.0 ± 10.4	74.4 ± 9.4	-2.9833	.004 Sig

	5 min after intubation	77.1 ± 11.5	72.1 ± 9.8	-1.9197	.040. Sig
Systolic blood pressure (mm Hg)	Base line	138.7 ± 11.8	136.6 ± 12.9	-0.7680	.449 NS
	3 min after study drug	131.6 ± 9.6	123.4 ± 11.7	-3.4314	.001 Sig
	1 min after induction	117.9 ± 13.0	110.9 ± 14.1	-2.3204	.023 Sig
	1 min after intubation	136.9 ± 12.6	123.7 ± 16.1	-4.0929	.001 Sig
	3 min after intubation	124.7 ± 19.6	108.2 ± 14.6	-4.2447	.001 Sig
	5 min after intubation	116.3 ± 14.9	100.3 ± 13.5	-5.0290	.001 Sig
Diastolic blood pressure (mm Hg)	Base line	82.2 ± 9.1	83.5 ± 9.0	0.6575	.513 NS
	3 min after study drug	79.0 ± 8.9	78.9 ± 8.6	-0.0896	.929 NS
	1 min after induction	71.7 ± 10.9	71.4 ± 10.8	-0.1235	.902 NS
	1 min after intubation	89.5 ± 13.0	80.9 ± 14.0	-2.8522	.006 Sig
	3 min after intubation	79.1 ± 14.9	68.2 ± 12.3	-3.5578	.001 Sig
	5 min after intubation	72.4 ± 13.0	62.2 ± 10.7	-3.8326	.001 Sig
Mean arterial pressure (mm Hg)	Base line	99.6 ± 8.4	99.2 ± 7.9	-0.2052	.826 NS
	3 min after study drug	95.8 ± 7.8	92.2 ± 7.5	-2.1082	.038 Sig
	1 min after induction	86.1 ± 9.7	83.5 ± 11	-1.1487	.254 NS
	1 min after intubation	104 ± 10.7	94.0 ± 14.5	-3.6401	.001 Sig
	3 min after intubation	93.0 ± 14.4	81.4 ± 12.0	-3.9221	.001 Sig
	5 min after intubation	86.0 ± 12.3	74.1 ± 10.8	-4.5819	.001 Sig

NS – not significant, Sig - Significant

The comparison of hemodynamic parameters [Heart rate, systolic & diastolic blood pressure, and mean arterial pressure during the time intervals across the study groups are explained in **table 2**. In our study, group D (dexmedetomidine 0.75mcg/kg) had lower mean heart rate than group M (magnesium sulphate 30mg/kg) at all time intervals and was statistically significant at 3 minutes after study drug, 1 minute after induction, 1 minute, 3 minutes and 5 minutes after intubation ($p < 0.05$). Study group D (dexmedetomidine 0.75mcg/kg) had a statistically lower

mean systolic blood pressure compared to group M (magnesium sulphate 30mg/kg) at all post-infusion points, while the diastolic blood pressure in Group D remained significantly lower across the time points 1, 3 and 5 minutes after induction compared to Group M. (p value <0.05)

Table 3: Comparison of complications across the study groups, N=80

Complications	Group M	Group D	P-Value
Hypotension			
Yes	1(2.5%)	4(10%)	.166 NS
No	39 (97.5)	36 (90%)	
Bradycardia	0(0%)	0(0%)	Not applicable
Desaturation	0(0%)	0(0%)	

Table 3 explains the incidence of complications across the study groups. We noted that Group M reported complications (hypotension) in only 1 patient (2.5%) whereas Group D reported in 4 (10%) patients. None reported bradycardia and desaturation. **Fig 1** explains the change in heart rate, systolic blood pressure, diastolic blood pressure and mean arterial pressure, compared to baseline and the time point of measurement. We noted that Group M showed a significant change when compared to the baseline for all time points across all parameters, when compared to Group D [Data showed only in figures




Fig 1: Comparison of hemodynamic parameters [Heart rate, systolic & diastolic blood pressure, and mean arterial pressure during the time intervals within the study groups, N=80

4. Discussion:

We performed a randomised control trial to evaluate the effectiveness and complications of magnesium sulphate and dexmedetomidine in attenuating hemodynamic stress response, where we noted that the sociodemographic and anatomical factors associated with difficult spinal anaesthesia among women who deliver through caesarean section in a tertiary care institute. We finally found that anatomical factors played a major deterministic role in predicting difficult spinal anaesthesia.

Our study concluded that dexmedetomidine was superior to magnesium sulfate in terms of heart rate regulation. In comparison to group M (magnesium sulfate 30 mg/kg), group D (dexmedetomidine 0.75 mcg/kg) showed consistently reduced mean heart rates at several time intervals, including 3 minutes post-drug administration and 1, 3, and 5 minutes post-intubation. These findings are consistent with research by Chhaya Joshi et al.^[11] and Krishna Chaithanya et al.^[10], which at similar intervals following intubation, both found significant heart rate reductions with dexmedetomidine over magnesium sulfate. On the other hand, magnesium sulfate caused a progressive reduction in heart rate upon intubation, following an initial spike as seen by Joshi et al.^[11] Because of its higher sympatholytic effects, dexmedetomidine appears to provide more constant and quick control over the hemodynamic response to intubation, as evidenced by this differential reaction.

Again, dexmedetomidine was better at preserving lower systolic blood pressure levels after intubation. The results showed that, in comparison to group M, group D's mean systolic blood pressure was considerably lower at all time points during the trial. These results are in line with those of Bidyut Borah et al., who found that dexmedetomidine reduced systolic blood pressure more than magnesium sulfate did at 1, 3, and 5 minutes after intubation.^[12] A similar pattern was noted by Chhaya Joshi et al., who found that dexmedetomidine improved systolic pressure management immediately after intubation as well as two and five minutes later.^[11] However, some investigations, like those by Basheer Ahmed Khan and Poonam Ghodki, found no substantial difference between the two medications, possibly due to changes in dosage and infusion intervals.^[13,14] On the other hand, it's possible that the current study's reduced dexmedetomidine dosage improved its ability to regulate systolic blood pressure without leading to severe hypotension.

In terms of diastolic blood pressure, dexmedetomidine likewise showed better effectiveness. In the current trial, there was a statistically significant decrease in diastolic blood pressure at 1, 3, and 5 minutes post-intubation with dexmedetomidine, but there was no significant difference between the groups at baseline or right after induction. This is consistent with research by Bidyut Borah et al. and Chhaya Joshi et al., which showed that dexmedetomidine, as opposed to magnesium sulfate, more successfully reduced diastolic blood pressure during laryngoscopy.^[11,12] Nonetheless, some research, including that conducted by Basheer Ahmed Khan and Krishna Chaithanya et al.,^[10] discovered that both medications were equally successful in regulating diastolic pressure. The

differences in patient groups, dose, and infusion methods could be the cause of these disparities. However, the overall pattern of these and other research' findings points to dexmedetomidine as a more dependable means of controlling diastolic blood pressure during intubation.^[15-17]

In terms of complications, both magnesium sulfate and dexmedetomidine revealed a reasonably low frequency of side events. Ten percent of patients receiving dexmedetomidine and 2.5 percent of patients receiving magnesium had hypotension; however, all cases were treated with fluid replacement, necessitating no therapeutic measures. Since both groups were dosed appropriately and patients were premedicated with glycopyrrolate, neither group of patients exhibited bradycardia or desaturation. These results are in line with research by Chhaya Joshi et al.^[11] in which hypotension was reported by 10% of patients treated with dexmedetomidine, although no serious side effects were reported. The negligible side effects with both drugs were confirmed by tests conducted by Poonam Ghodki, Bidyut Borah, and Mahajan L et al.,^[12,14,18] indicating their safety profiles for clinical use. When compared to magnesium sulfate, dexmedetomidine seems to provide a more effective overall attenuation of the hemodynamic stress response, albeit at a slightly higher but still manageable risk of hypotension.^[19,20] Thus based on our study findings we recommend the use of dexmedetomidine in attenuation of stress responses to intubation, and we also recommend to do further studies on dexmedetomidine and magnesium sulphate to evaluate other anaesthetic parameters like depth of anaesthesia and attenuation of extubation response

Our study had the strength that it is one among few studies from a south Indian setting that has tried to compare the effectiveness of magnesium sulphate and dexmedetomidine in attenuating hemodynamic stress response. We have used randomisation to strengthen our findings. Our study also had a few limitations, in our study, the measurement of plasma catecholamine level was not considered, and we included only patients with ASA physical status I and II in our study, however, dexmedetomidine and magnesium sulphate may be useful in cardiac patients. And finally, the effects of dexmedetomidine and magnesium sulphate on haemodynamic parameters during intraoperative and postoperative periods were not included in our study.

5. Conclusion:

From our study, we conclude that dexmedetomidine in a dose of 0.75 mcg/kg significantly attenuates the haemodynamic stress response to laryngoscopy and endotracheal intubation when compared to magnesium sulphate in a dose of 30 mg/kg. Dexmedetomidine consistently showed superior hemodynamic stability, particularly in the reduction of systolic and diastolic blood pressure, which aligns with findings from previous studies. Although both agents were effective, dexmedetomidine's ability to maintain lower blood pressure and heart rate throughout the procedure suggests its greater potency in mitigating the cardiovascular stress response during airway manipulation. We also found that both drugs are devoid of any significant adverse effects like hypotension, bradycardia and desaturation.

CONSENT (WHEREEVER APPLICABLE)

Informed written consent taken

ETHICAL APPROVAL (WHEREEVER APPLICABLE)

The patient and attendees were explained about the procedure and the expected complications. They were informed about the present study and their eligibility for participating in the study. Only patients who were willing to participate were included and informed consent was obtained. The study was approved by the Institutional Ethical Committee [NBE/CNC/CET/41159]

REFERENCES

1. Popat B, Jones AT. Invasive and non-invasive mechanical ventilation. *Medicine (Abingdon)*. 2016 Jun;44(6):346-350.
2. Sarkar J, Anand T, Kamra SK. Hemodynamic response to endotracheal intubation using C-Trach assembly and direct laryngoscopy. *Saudi J Anaesth*. 2015 Oct-Dec;9(4):343-7. doi: 10.4103/1658-354X.154702. PMID: 26543446; PMCID: PMC4610073.
3. Sener EB, Ustun E, Ustun B, Sarihasan B. Hemodynamic responses and upper airway morbidity following tracheal intubation in patients with hypertension: conventional laryngoscopy versus an intubating laryngeal mask airway. *Clinics (Sao Paulo)*. 2012;67(1):49-54. doi: 10.6061/clinics/2012(01)08. PMID: 22249480; PMCID: PMC3248601.
4. Foote AG, Thibeault SL. Sensory Innervation of the Larynx and the Search for Mucosal Mechanoreceptors. *J Speech Lang Hear Res*. 2021 Feb 17;64(2):371-391. doi: 10.1044/2020_JSLHR-20-00350. Epub 2021 Jan 19. PMID: 33465318; PMCID: PMC8632506.
5. Bruder N, Ortega D, Granthil C. Consequences and prevention methods of hemodynamic changes during laryngoscopy and intratracheal intubation. *Ann Fr Anesth Reanim*. 1992 Jan 1;11(1):57-71.
6. Giovannitti JA Jr, Thoms SM, Crawford JJ. Alpha-2 adrenergic receptor agonists: a review of current clinical applications. *Anesth Prog*. 2015 Spring;62(1):31-9. doi: 10.2344/0003-3006-62.1.31. PMID: 25849473; PMCID: PMC4389556.
7. Misganaw A, Sitote M, Jemal S, Melese E, Hune M, Seyoum F, et al. Comparison of intravenous magnesium sulphate and lidocaine for attenuation of cardiovascular response to laryngoscopy and endotracheal intubation in elective surgical patients at Zewditu Memorial Hospital Addis Ababa, Ethiopia. *PLoS One*. 2021 Jun 1;16(6):e0252465. doi: 10.1371/journal.pone.0252465. PMID: 34061894; PMCID: PMC8168879.
8. Shin HJ, Na HS, Do SH. Magnesium and Pain. *Nutrients*. 2020 Jul 23;12(8):2184. doi: 10.3390/nu12082184. PMID: 32718032; PMCID: PMC7468697.

9. Vora KS, Baranda U, Shah VR, Modi M, Parikh GP, Butala BP. The effects of dexmedetomidine on attenuation of hemodynamic changes and there effects as adjuvant in anesthesia during laparoscopic surgeries. *Saudi J Anaesth.* 2015 Oct-Dec;9(4):386-92. doi: 10.4103/1658-354X.159461. PMID: 26543454; PMCID: PMC4610081.
10. Chaithanya K, Vaddineni J, Reddy N, Gandra S, Kumar C, Rao V, et al. A comparative study between IV 50% magnesium sulphate and dexmedetomidine for attenuation of cardiovascular stress response during laryngoscopy and endotracheal intubation. *J Evol Med Dent Sci.* 2014 Aug 4;3(32):8741–50.
11. Joshi C, Ganeshnavar A, Masur Sh A. Comparative study between intra venous dexmedetomidine and magnesium sulfate in attenuation of cardiovascular response to laryngoscopy and endotracheal intubation—a randomized clinical trial. *Intl J Clin Diag Res.* 2016 Jun;4(3):II
12. Borah B, Shukla MI, Joshi NK. A comparative study between dexmedetomidine, clonidine and magnesium sulfate in attenuating hemodynamic response to laryngoscopy and intubation—a randomised study. *Indian J Clin Anaesth.* 2017 Mar 15;4(1):30–36.
13. Khan BA, Mahtalath MD. Attenuation of cardiovascular responses to laryngoscopy and intubation-dexmedetomidine vs. magnesium sulfate. *J Evid Based Med Heal.* 2017 Jan 30;4(9):495–8.
14. Ghodki P, Sawle VM. Comparative study between magnesium sulphate and dexmedetomidine for attenuation of vasopressor stress response during laryngoscopy and endotracheal intubation. *Int J Med Anesthesiol.* 2020 Jul 1;3(3):63–7.
15. Kopargaonkar S, Maybauer M, Kulkarni A. Magnesium sulphate as an adjuvant to fentanyl for attenuation of intubation response. *Br J Anaesth.* 2018 May 1;120(5):e15–6.
16. Alam MS, Kumar V, Hussain A, Kumar A, Yadav A. Variations in Circulatory Responses to Laryngoscopy-Dexmedetomidine vs. Magnesium Sulphate. *Ann Int Med Dent Res.* 2017;3(4):AN18-21.
17. Kumari K, Gombar S, Kapoor D, Sandhu HS. Clinical study to evaluate the role of preoperative dexmedetomidine in attenuation of hemodynamic response to direct laryngoscopy and tracheal intubation. *Acta Anaesthesiol Taiwan.* 2015 Dec;53(4):123–30.
18. Mahajan L, Kaur M, Gupta R, Aujla KS, Singh A, Kaur A. Attenuation of the pressor responses to laryngoscopy and endotracheal intubation with intravenous dexmedetomidine versus magnesium sulphate under bispectral index-controlled anaesthesia: A placebo-controlled prospective randomised trial. *Indian J Anaesth.* 2018 May;62(5):337–43.
19. Sebastian B, Talikoti AT, Krishnamurthy D. Attenuation of haemodynamic responses to laryngoscopy and endotracheal intubation with intravenous dexmedetomidine: A comparison between two doses. *Indian J Anaesth.* 2017 Jan;61(1):48.
20. Kotwani MB, Kotwani DM, Laheri V. A comparative study of two doses of magnesium sulphate in attenuating haemodynamic responses to laryngoscopy and intubation. *Int J Res Med Sci.* 2016 Jul;4(7):2548–55.

UNDER PEER REVIEW